Arnold & Porter’s Preeminent Life Sciences Work Honored Seven Times at 9th Annual LMG Life Sciences Awards
Arnold & Porter’s renowned life sciences legal work was recognized seven times at the ninth annual LMG Life Sciences Awards on September 22, 2021. In addition to winning three "Firm of the Year" designations and two "Impact Case of the Year" awards for life sciences, regulatory and intellectual property matters, two Arnold & Porter attorneys were celebrated for their standout individual work.
The firm was recognized in the following areas:
- Life Cycle Firm of the Year – United States
- Regulatory Firm of the Year
- Firm of the Year – Intellectual Property
- Impact Case of the Year: Amgen v. Sanofi (Fed Cir 2021)
- Impact Case of the Year: Hologic v. Minerva (US Supreme Ct 2021)
- Regulatory Attorney of the Year: FDA Pharmaceutical – Daniel Kracov
- Hall of Fame - Saul Morgenstern
Life Sciences & Healthcare Regulatory practice co-head Daniel Kracov’s continuing work in advising companies working to combat the COVID-19 pandemic earned him "Regulatory Attorney of the Year: FDA Pharmaceutical" for the third time in four years. Kracov continued to represent AstraZeneca in 2021 on matters relating to its COVID-19 vaccine, as well as advising numerous leading life sciences companies on novel issues arising from the development of drugs, biologics, medical devices and diagnostics.
Senior counsel Saul Morgenstern was inducted into the LMG Life Sciences "Hall of Fame" for his lifelong contributions to the legal world and his outstanding work in the antitrust space. Morgenstern represents clients across a broad spectrum of industries, including brand name and generic pharmaceutical manufacturers, diagnostics companies and medical device manufacturers in complex antitrust and other commercial disputes. Morgenstern previously was honored by LMG in 2015 as "Antitrust Litigator of the Year."
The firm was recognized as "US Life Cycle Firm of the Year" for its excellence in the key areas LMG Life Sciences recognizes, including antitrust, intellectual property, regulatory, financial and corporate, and non-IP litigation and enforcement.
The firm also was named "Regulatory Firm of the Year" by LMG for its formidable presence in the field of life sciences advising major pharmaceutical companies on issues related to COVID-19, price reporting matters and anti-kickback compliance.
The recognition of "Intellectual Property Firm of the Year" is a testament to the breadth and depth of the Intellectual Property practice group. The practice secured numerous victories this year, including for Hologic and Sanofi and Regeneron, leading to LMG naming two of those matters as "Impact Case of the Year." In Hologic v. Minerva, Arnold & Porter prevailed before the US Supreme Court on behalf of longtime client Hologic on the issue of "assignor estoppel," an equitable doctrine that prevents those who assign/sell patent rights from later challenging the validity of the rights they sold. In Amgen Inc. v. Sanofi, Arnold & Porter earned an important win for Sanofi and Regeneron earlier this year before the Federal Circuit on the issue of the "enablement" of patent claims covering therapeutic antibodies.